Angiostatin expression in ovarian cancer

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1225-1230

  Yabushita, Hiromitsu ^a   Noguchi, Mari ^a   Obayashi, Yukihiko ^a   Kishida, Tameko ^a   Noguchi, Yasuyuki ^a   Sawaguchi, Keizo ^a   Noguchi, Masayoshi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Angiostatin; Ovarian cancer; Prognosis; VEGF

Indexed keywords

ANGIOSTATIN; VASCULOTROPIN A;

ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROCIRCULATION; MORTALITY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PROGNOSIS; RISK FACTOR; TIME; TUMOR CELL LINE;

ANGIOSTATINS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROCIRCULATION; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2142690653     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1225     Document Type: Article

References (21)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
3. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
4. Cao Y, O'Reilly MS, Marshall B, Flynn E, Richard-Weidong J and Folkman J: Expression of angiostatin in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101: 1055-1063, 1998. (Pubitemid 28125284)
5. O'Reilly MS: The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 15: 5-13, 1997.
6. Volm M, Koomagi R and Mattern J: Prognostic value of vascular endothelial growth factor and its receptor FLT-1 in squamous cell lung cancer. Int I Cancer Prediatr Oncol 74: 64-68, 1997. (Pubitemid 27157857)
7. Volm M, Koomagi R, Mattern J and Stammler G: Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 33: 691-693, 1997. (Pubitemid 27223759)
8. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994. (Pubitemid 24324921)
9. Lannutti BJ, Gately ST, Quevedo ME, Soff GA and Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997. (Pubitemid 27516363)
10. O'Reilly MS, Holmgren L, Chen C and Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692, 1996. (Pubitemid 26191958)
11. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrups P, Everitt L, Hubchak S, Schnaper HW and Pizzo SV: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816, 1999. (Pubitemid 29148800)
12. Senger DR, van de Walter L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackmann RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Met Rev 12: 303-324, 1993. (Pubitemid 23293287)
13. Neufeld G, Tessler S, Gitay-goren H, Cohen T and Levi BZ: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5: 89-97, 1994.
14. Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K and Noguchi M: Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 10: 89-95, 2003.
15. Yamamoto S, Konishi I, Mandai M, Kuroda H, Nanbu K, Sakahara H and Mori T: Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76: 1221-1227, 1997. (Pubitemid 27448021)
16. Paley PJ, Staskus KA, Gebhard K, Mohanrai D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106, 1997. (Pubitemid 27270925)
17. Volm M, Mattern J and Koomagi R: Angiostatin expression in non-small cell lung cancer. Clin Cancer Res 6: 3236-3240, 2000. (Pubitemid 30637753)
18. Kirsch M, Strasser J, Allende R, Bello L, Zhang J and Black PM: Angiostatin supresses malignant glioma growth in vivo. Cancer Res 58: 4654-4659, 1998. (Pubitemid 28480631)
19. Cao Y: Therapeutic potentials of angiostatin in the treatment of cancer. Hematologica 84: 643-650, 1999.
20. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998. (Pubitemid 28465848)
21. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ and Fidler IJ: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor trypsin kinases. Int J Oncol 16: 445-454, 2000.